Mesulergine (CU32‐085) in the treatment of Parkinson's disease

Ronald F. Pfeifer; Kathleen Wilken; Carolyn Glaeske

doi:10.1002/ana.410170405

Mesulergine (CU32‐085) in the treatment of Parkinson's disease

Ronald F. Pfeifer, Kathleen Wilken, Carolyn Glaeske

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Twenty patients with Parkinson's disease were treated with the 8‐α‐ergoline derivative mesulergine. Participants were divided into two groups, and over a nine‐week period, mesulergine dosage was increased to amaximum of either 10 or 20 mg daily. During this time levodopa‐carbidopa (LD‐CD) dosage was reduced and treatement was discontinued if possible. The dosage of LD‐CD was reduced 75% in the 10 mg group and 74% in the 20 mg group. Patients in the low dose group maintained in each of the cardinal signs of parkinsonism. Adverse effects were generally mild and infrequent. Many adverse effects induced by LD‐CD diminished or resolved. Our results suggest that mesulergine can be valuable in the management of Parkinson's disease, particularly in those individuals experiencing dose‐limiting adverse effects from LD‐CD.

Original language	English (US)
Pages (from-to)	334-336
Number of pages	3
Journal	Annals of Neurology
Volume	17
Issue number	4
DOIs	https://doi.org/10.1002/ana.410170405
State	Published - Apr 1985
Externally published	Yes

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/ana.410170405

Cite this

@article{632948df34b443e7ad2b6f4c068457cd,

title = "Mesulergine (CU32‐085) in the treatment of Parkinson's disease",

abstract = "Twenty patients with Parkinson's disease were treated with the 8‐α‐ergoline derivative mesulergine. Participants were divided into two groups, and over a nine‐week period, mesulergine dosage was increased to amaximum of either 10 or 20 mg daily. During this time levodopa‐carbidopa (LD‐CD) dosage was reduced and treatement was discontinued if possible. The dosage of LD‐CD was reduced 75% in the 10 mg group and 74% in the 20 mg group. Patients in the low dose group maintained in each of the cardinal signs of parkinsonism. Adverse effects were generally mild and infrequent. Many adverse effects induced by LD‐CD diminished or resolved. Our results suggest that mesulergine can be valuable in the management of Parkinson's disease, particularly in those individuals experiencing dose‐limiting adverse effects from LD‐CD.",

author = "Pfeifer, {Ronald F.} and Kathleen Wilken and Carolyn Glaeske",

year = "1985",

month = apr,

doi = "10.1002/ana.410170405",

language = "English (US)",

volume = "17",

pages = "334--336",

journal = "Annals of Neurology",

issn = "0364-5134",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Mesulergine (CU32‐085) in the treatment of Parkinson's disease

AU - Pfeifer, Ronald F.

AU - Wilken, Kathleen

AU - Glaeske, Carolyn

PY - 1985/4

Y1 - 1985/4

N2 - Twenty patients with Parkinson's disease were treated with the 8‐α‐ergoline derivative mesulergine. Participants were divided into two groups, and over a nine‐week period, mesulergine dosage was increased to amaximum of either 10 or 20 mg daily. During this time levodopa‐carbidopa (LD‐CD) dosage was reduced and treatement was discontinued if possible. The dosage of LD‐CD was reduced 75% in the 10 mg group and 74% in the 20 mg group. Patients in the low dose group maintained in each of the cardinal signs of parkinsonism. Adverse effects were generally mild and infrequent. Many adverse effects induced by LD‐CD diminished or resolved. Our results suggest that mesulergine can be valuable in the management of Parkinson's disease, particularly in those individuals experiencing dose‐limiting adverse effects from LD‐CD.

AB - Twenty patients with Parkinson's disease were treated with the 8‐α‐ergoline derivative mesulergine. Participants were divided into two groups, and over a nine‐week period, mesulergine dosage was increased to amaximum of either 10 or 20 mg daily. During this time levodopa‐carbidopa (LD‐CD) dosage was reduced and treatement was discontinued if possible. The dosage of LD‐CD was reduced 75% in the 10 mg group and 74% in the 20 mg group. Patients in the low dose group maintained in each of the cardinal signs of parkinsonism. Adverse effects were generally mild and infrequent. Many adverse effects induced by LD‐CD diminished or resolved. Our results suggest that mesulergine can be valuable in the management of Parkinson's disease, particularly in those individuals experiencing dose‐limiting adverse effects from LD‐CD.

UR - http://www.scopus.com/inward/record.url?scp=0021832018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021832018&partnerID=8YFLogxK

U2 - 10.1002/ana.410170405

DO - 10.1002/ana.410170405

M3 - Article

C2 - 3890700

AN - SCOPUS:0021832018

SN - 0364-5134

VL - 17

SP - 334

EP - 336

JO - Annals of Neurology

JF - Annals of Neurology

IS - 4

ER -

Mesulergine (CU32‐085) in the treatment of Parkinson's disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this